-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Colorectal cancer ranks third in global incidence and second in mortality
.
For patients with advanced colorectal cancer who have progressed to standard first-line and second-line treatments, third-line treatments include regorafenib, fruquintinib, and TAS-102, but the efficacy is moderate
Colorectal cancer ranks third in global incidence and second in mortality
The study retrospectively collected data from patients with MSS or pMMR mCRC from June 2019 to March 2021
.
The analysis compared the efficacy and safety of FP and RP
The study retrospectively collected data from patients with MSS or pMMR mCRC from June 2019 to March 2021
A total of 51 patients were included in the study, of which 28 were treated with FP regimen and 23 were treated with RP regimen
The ORR of the whole population was 7.
Efficacy evaluation
Efficacy evaluationThe median progression-free survival (PFS) of the FP group was 6.
4 months (HR = 0.
445; 95% CI: 5.
527-7.
273), and the RP group was 3.
9 months (HR = 0.
594; 95% CI: 2.
736-5.
064).
The difference It is statistically significant (P = 0.
0209)
.
4 months (HR = 0.
445; 95% CI: 5.
527-7.
273), and the RP group was 3.
9 months (HR = 0.
594; 95% CI: 2.
736-5.
064).
The difference It is statistically significant (P = 0.
0209)
.
The median progression-free survival (PFS) of the FP group was 6.
PFS
PFSPFSAmong patients without liver metastasis, the median progression-free survival (PFS) between the FP group and the RP group was significantly different (P<0.
0001), but there was no statistically significant difference in patients with liver metastasis (P>0.
05)
.
For KRAS wild-type patients, the median PFS between the FP group and the RP group was significantly different (P=0.
Among patients without liver metastasis, the median progression-free survival (PFS) between the FP group and the RP group was significantly different (P<0.
Subgroup analysis PFS
Subgroup analysis PFSThe adverse events of 28 patients in the FP group and 23 patients in the RP group were evaluated
.
All patients experienced adverse events
The adverse events of 28 patients in the FP group and 23 patients in the RP group were evaluated
Multivariate analysis showed that the treatment of fruquintinib versus regorafenib was an independent risk factor for PFS (HR = 2.
688; 95%CI: 1.
246 5.
797; P = 0.
012)
.
Multivariate analysis showed that the treatment of fruquintinib versus regorafenib was an independent risk factor for PFS (HR = 2.
688; 95%CI: 1.
246 5.
797; P = 0.
012)
.
Multivariate PFS risk factors
Multivariate PFS risk factorsIn summary, the study shows that Fruquintinib + PD-1 inhibitor (FP) can improve PFS in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer
.
.
The study showed that Fruquintinib + PD-1 inhibitor (FP) can improve PFS in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer
.
The study showed that Fruquintinib + PD-1 inhibitor (FP) can improve PFS in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer
.
Original source:
Original source:Sun L, Huang S, Li D, Mao Y, Wang Y and Wu J (2021) Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer.
Front.
Oncol.
11 :754881.
doi: 10.
3389/fonc.
2021.
754881
Front.
Oncol.
11 :754881.
doi: 10.
3389/fonc.
2021.
754881 leave a message here
